299 related articles for article (PubMed ID: 26569500)
21. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV.
Lévi FA; Boige V; Hebbar M; Smith D; Lepère C; Focan C; Karaboué A; Guimbaud R; Carvalho C; Tumolo S; Innominato P; Ajavon Y; Truant S; Castaing D; De Baere T; Kunstlinger F; Bouchahda M; Afshar M; Rougier P; Adam R; Ducreux M;
Ann Oncol; 2016 Feb; 27(2):267-74. PubMed ID: 26578731
[TBL] [Abstract][Full Text] [Related]
22. Avatars Identify Genetic Sources of Drug Response.
Cancer Discov; 2016 Jan; 6(1):OF9. PubMed ID: 26573662
[TBL] [Abstract][Full Text] [Related]
23. Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies.
Hubbard JM; Kim G; Borad MJ; Johnson E; Qin R; Lensing J; Puttabasavaiah S; Wright J; Erlichman C; Grothey A
Invest New Drugs; 2016 Feb; 34(1):96-103. PubMed ID: 26581401
[TBL] [Abstract][Full Text] [Related]
24. von Willebrand Factor-Rich Platelet Thrombi in the Liver Cause Sinusoidal Obstruction Syndrome following Oxaliplatin-Based Chemotherapy.
Nishigori N; Matsumoto M; Koyama F; Hayakawa M; Hatakeyayama K; Ko S; Fujimura Y; Nakajima Y
PLoS One; 2015; 10(11):e0143136. PubMed ID: 26580395
[TBL] [Abstract][Full Text] [Related]
25. Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival.
Osumi H; Shinozaki E; Osako M; Kawazoe Y; Oba M; Misaka T; Goto T; Kamo H; Suenaga M; Kumekawa Y; Ogura M; Ozaka M; Matsusaka S; Chin K; Hatake K; Mizunuma N
Mol Clin Oncol; 2015 Sep; 3(5):1053-1057. PubMed ID: 26623049
[TBL] [Abstract][Full Text] [Related]
26. A Comprehensive Review of Clinical Trials on EGFR Inhibitors Such as Cetuximab and Panitumumab as Monotherapy and in Combination for Treatment of Metastatic Colorectal Cancer.
Yazdi MH; Faramarzi MA; Nikfar S; Abdollahi M
Avicenna J Med Biotechnol; 2015; 7(4):134-44. PubMed ID: 26605007
[TBL] [Abstract][Full Text] [Related]
27. Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies.
Scarpace SL
Drugs Context; 2015; 4():212289. PubMed ID: 26576187
[TBL] [Abstract][Full Text] [Related]
28. Cetuximab could be more effective without prior bevacizumab treatment in metastatic colorectal cancer patients.
Sato Y; Matsusaka S; Suenaga M; Shinozaki E; Mizunuma N
Onco Targets Ther; 2015; 8():3329-36. PubMed ID: 26648737
[TBL] [Abstract][Full Text] [Related]
29. Q-TWiST analysis of panitumumab plus FOLFOX4 versus FOLFOX4 alone in patients with previously untreated wild-type RAS metastatic colorectal cancer.
Wang J; Hechmati G; Dong J; Maglinte GA; Barber B; Douillard JY
Curr Med Res Opin; 2016; 32(3):459-65. PubMed ID: 26613286
[TBL] [Abstract][Full Text] [Related]
30. KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study.
Dadduzio V; Basso M; Rossi S; Cenci T; Capodimonti S; Strippoli A; Orlandi A; Cerchiaro E; Schinzari G; Cassano A; Martini M; Barone C
Mol Diagn Ther; 2016 Feb; 20(1):65-74. PubMed ID: 26610798
[TBL] [Abstract][Full Text] [Related]
31. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
Kim J; Lee J; Kim C; Choi J; Kim A
Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
[TBL] [Abstract][Full Text] [Related]
32. Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor.
Spector NL; Robertson FC; Bacus S; Blackwell K; Smith DA; Glenn K; Cartee L; Harris J; Kimbrough CL; Gittelman M; Avisar E; Beitsch P; Koch KM
PLoS One; 2015; 10(11):e0142845. PubMed ID: 26571496
[TBL] [Abstract][Full Text] [Related]
33. Microenvironment-Driven Resistance to BRAF Inhibition Comes of Age.
Menon DR; Schaider H
J Invest Dermatol; 2015 Dec; 135(12):2923-2925. PubMed ID: 26569587
[TBL] [Abstract][Full Text] [Related]
34. HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer.
Takegawa N; Yonesaka K; Sakai K; Ueda H; Watanabe S; Nonagase Y; Okuno T; Takeda M; Maenishi O; Tsurutani J; Satoh T; Okamoto I; Nishio K; Tamura T; Nakagawa K
Oncotarget; 2016 Jan; 7(3):3453-60. PubMed ID: 26657506
[TBL] [Abstract][Full Text] [Related]
35. Predictability of antitumor efficacy of cetuximab plus irinotecan based on skin rash severity according to observation period in patients with metastatic colorectal cancer following failure of fluorouracil, irinotecan and oxaliplatin.
Horie Y; Yamazaki K; Funakoshi T; Hamauchi S; Taniguchi H; Tsushima T; Todaka A; Machida N; Taku K; Fukutomi A; Onozawa Y; Yasui H; Mizukami T; Izawa N; Hirakawa M; Tsuda T; Nakajima T; Boku N
Mol Clin Oncol; 2015 Sep; 3(5):1029-1034. PubMed ID: 26623045
[TBL] [Abstract][Full Text] [Related]
36. Maintenance strategy in metastatic colorectal cancer: A systematic review.
Esin E; Yalcin S
Cancer Treat Rev; 2016 Jan; 42():82-90. PubMed ID: 26608114
[TBL] [Abstract][Full Text] [Related]
37. Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Nintedanib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Colorectal Cancer Refractory to Standard Treatment.
Van Cutsem E; Yoshino T; Hocke J; Oum'Hamed Z; Studeny M; Tabernero J
Clin Colorectal Cancer; 2016 Mar; 15(1):91-94.e1. PubMed ID: 26603056
[TBL] [Abstract][Full Text] [Related]
38. Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients.
Li J; Srivastava RM; Ettyreddy A; Ferris RL
J Immunother Cancer; 2015; 3():54. PubMed ID: 26579227
[TBL] [Abstract][Full Text] [Related]
39. Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients.
Tolaney SM; Boucher Y; Duda DG; Martin JD; Seano G; Ancukiewicz M; Barry WT; Goel S; Lahdenrata J; Isakoff SJ; Yeh ED; Jain SR; Golshan M; Brock J; Snuderl M; Winer EP; Krop IE; Jain RK
Proc Natl Acad Sci U S A; 2015 Nov; 112(46):14325-30. PubMed ID: 26578779
[TBL] [Abstract][Full Text] [Related]
40. Analysis of 473 US Head and Neck Cancer Trials (1996-2014): Trends, Gaps, and Opportunities.
Devaiah A; Murchison C
Otolaryngol Head Neck Surg; 2016 Feb; 154(2):309-14. PubMed ID: 26577773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
